High affinity t cell receptor and use thereof
AssigneeMax-Delbrueck-Centrum fur Molekulare Medizin Berlin-Buch
InventorsDolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.
Claims21
A nucleic acid molecule coding for the V(D)J regions of a TCR that recognizes a tumor antigen and comprising the nucleic acid sequence of SEQ ID NO:
- 1 coding for the α-chain and/or the nucleic acid sequence of SEQ ID NO:
- 2 coding for the β-chain of said TCR,
- or
- a derivative thereof, coding for the α- or β-chain, wherein the chain has been altered by one or more additions or deletions of from 1-15 amino acids, the additions or deletions being outside the CDR3 region of each chain and/or by conservative substitutions of from 1-15 amino acids, wherein the tumor antigen recognizing characteristics are maintained or improved,
- or
- a fragment thereof coding for a CDR3 region of a TCR recognizing a tumor antigen and having the nucleic acid sequence of SEQ ID NO:
- 3 or 4 or coding for the amino acid sequences of SEQ ID NO:
- 5 or 6,
- or
- a derivative of said fragment, wherein the CDR3 region has been altered by one or more additions and/or deletions of an overall number of from 1-5 amino acids, but not more than 1-3 contiguous amino acids and/or conservative substitutions of from 1-6 amino acids and wherein the tumor antigen recognizing characteristics are maintained or improved.
2-3. (canceled)
10-11. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.